Advances in Therapy

, Volume 28, Supplement 7, pp 7–13

Extramedullary plasmacytomas in the context of multiple myeloma

  • Beatriz Aguado
  • Belen Iñigo
  • Jose L. Sastre
  • Albert Oriol
Clinical Cases

Abstract

Plasmacytoma is a frequent complication of multiple myeloma, either at diagnosis or within disease progression. The extramedullary disease confers a poorer prognosis and is biologically distinct with high-risk molecular and histological features, being resistant to conventional treatments. Radiation therapy remains the most effective treatment for extramedullary lesions to achieve local control. There are very limited data from randomized trials regarding the most appropriate systemic treatment. Case reports such as those presented here, as well as retrospective analysis of series, suggest that lenalidomide is an effective agent, in combination with dexamethasone, in this setting. Additional studies are needed to define the proper management of this condition.

Keywords

extramedullary disease lenalidomide multiple myeloma plasmacytoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dores GM, Landgren O, McGlynn KA, et al. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992–2004. Br J Haematol. 2009;144:86–94.PubMedCrossRefGoogle Scholar
  2. 2.
    Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21:325–330.PubMedCrossRefGoogle Scholar
  3. 3.
    Cerny J, Fadare O, Hutchinson L, Wang SA. Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol. 2008;81:65–69.PubMedCrossRefGoogle Scholar
  4. 4.
    Wu P, Davies FE, Boyd K, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50:230–235.PubMedCrossRefGoogle Scholar
  5. 5.
    Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A. Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol. 2010;150:418–427.PubMedCrossRefGoogle Scholar
  6. 6.
    Katodritou E, Gastari V, Verrou E, et al. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leuk Res. 2009;33:1137–1140.PubMedCrossRefGoogle Scholar
  7. 7.
    Sheth N, Yeung J, Chang H. p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. Leuk Res. 2009;33:1357–1360.PubMedCrossRefGoogle Scholar
  8. 8.
    Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica. 2007;92:143–144.PubMedCrossRefGoogle Scholar
  9. 9.
    López-Anglada L, Gutiérrez NC, García JL, et al. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma. Eur J Haematol. 2010;84:359–361.PubMedCrossRefGoogle Scholar
  10. 10.
    Calvo-Villas JM, Alegre A, Calle C, et al. Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma. Eur J Haematol. 2011;87:281–284.PubMedCrossRefGoogle Scholar
  11. 11.
    Alegre A, Aguado B, Giraldo P, et al. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. Int J Hematol. 2011;93:351–360.PubMedCrossRefGoogle Scholar
  12. 12.
    Rosinol L, Cibeira MT, Blade J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89:832–836.PubMedGoogle Scholar
  13. 13.
    Nakazato T, Suzuki K, Mihara A, et al. Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone. Intern Med. 2009;48:1827–1832.PubMedCrossRefGoogle Scholar
  14. 14.
    Gonzalez-Porras JR, Gonzalez M, Garcia-Sanz R, et al. Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas. Br J Haematol. 2002;119:883–884.PubMedCrossRefGoogle Scholar
  15. 15.
    Chim CS, Ooi GC, Loong F, Au AW, Lie AK. Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma. J Clin Oncol. 2005;23:2426–2428.PubMedCrossRefGoogle Scholar
  16. 16.
    Paubelle E, Coppo P, Garderet L, et al. Complete remission with bortezomib on plasmacytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia. 2005;19:1702–1704.PubMedCrossRefGoogle Scholar
  17. 17.
    Krauth MT, Bankier A, Valent P, Kalhs P, Drach J. Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. Leuk Res. 2005;29:1473–1477.PubMedCrossRefGoogle Scholar
  18. 18.
    Laura R, Cibeira MT, Uriburu C, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol. 2006;76:405–408.PubMedCrossRefGoogle Scholar
  19. 19.
    Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37.PubMedCrossRefGoogle Scholar
  20. 20.
    Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–2132.PubMedCrossRefGoogle Scholar
  21. 21.
    Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–2142.PubMedCrossRefGoogle Scholar
  22. 22.
    Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23:2147–2152.PubMedCrossRefGoogle Scholar
  23. 23.
    Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008;112:4445–4451.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Healthcare 2011

Authors and Affiliations

  • Beatriz Aguado
    • 1
  • Belen Iñigo
    • 2
  • Jose L. Sastre
    • 3
  • Albert Oriol
    • 4
  1. 1.Department of HematologyHospital Universitario de la PrincesaMadridSpain
  2. 2.Department of Hematology and HemotherapyHospital Universitario Clínico San CarlosMadridSpain
  3. 3.Department of HematologyComplexo Hospitalario OurenseOurenseSpain
  4. 4.Department of HematologyHospital Germans Trias i PujolBadalonaSpain

Personalised recommendations